Cencora (COR) Research | Aerarium Research

Forward Estimates

EPS Estimates

Current Qtr

$4.35

$4.30$4.42

vs $4.00+8.6%

11 analysts

Next Qtr

$4.58

$4.29$4.74

vs $3.84+19.3%

11 analysts

Current Yr

$17.75

$17.70$17.78

vs $16.00+11.0%

8 analysts

Next Yr

$19.78

$19.36$20.13

vs $17.75+11.4%

14 analysts

Revenue Estimates

Current Qtr

$84.21B

$82.63B$85.04B

vs $80.66B+4.4%

9 analysts

Next Qtr

$88.38B

$86.49B$90.35B

vs $83.73B+5.6%

9 analysts

Current Yr

$337.31B

$333.41B$340.00B

vs $321.33B+5.0%

12 analysts

Next Yr

$358.87B

$346.57B$372.36B

vs $337.31B+6.4%

12 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for COR on EDGAR.

COR filing events and research context
Filed	Item	Context
May 6, 2026	mda_quarterly	Cencora acquired OneOncology on February 2, 2026, for $7.387 billion to expand its U.S. specialty pharmaceutical leadership and community oncology provider network. Six-month revenue increased 4.7%, driven by strong unit volume growth in the U.S. Healthcare Solutions segment—specifically GLP-1 class diabetes and weight loss products—and growth in European distribution. Gross profit rose 18.6% over six months, aided by LIFO credits from declining manufacturer prices and the RCA and OneOncology acquisitions, though offset by reduced antitrust litigation gains. Operating expenses increased due to integration costs and a $249.5 million impairment of the U.S. Consulting Services business. Interest expenses climbed following the issuance of $3.0 billion in senior notes and $1.5 billion in term loans to fund the OneOncology transaction. Cash flow from operations shifted to a $1.0 billion outflow over six months, primarily due to a $2.2 billion decrease in accounts payable. The company carries a $4.3 billion accrued opioid litigation liability payable over 13 years. Primary risks include foreign exchange volatility—particularly the Turkish Lira and Euro—inflationary pressures on fuel and operating costs, and geopolitical instability in Ukraine and the Middle East.
Feb 4, 2026	mda_quarterly	Cencora reorganized its reporting into U.S. Healthcare Solutions, International Healthcare Solutions, and Other. Quarterly revenue rose 5.5% to $85.9 billion, driven by a $1.0 billion increase in GLP-1 diabetes and weight loss product sales and growth in European distribution. The company expanded its footprint through the $4.6 billion acquisition of OneOncology and the earlier acquisition of RCA. Gross profit increased 20.1% to $3.1 billion, supported by the RCA integration and a $70.2 million LIFO credit resulting from lower brand pharmaceutical prices. However, operating expenses rose 24.8%, including a $249.5 million impairment of the U.S. Consulting Services business. Net interest expense increased 159.2% due to new debt financing for acquisitions. Cash used in operations was $2.3 billion, largely reflecting a $3.5 billion inventory increase to support business volume. Cencora maintains a $4.3 billion accrued liability for opioid litigation, payable over 13 years. Financial analysts should monitor GLP-1 utilization trends, the rate of generic and biosimilar conversion, and foreign exchange volatility, particularly regarding the Turkish Lira.
Nov 25, 2025	business	COR operates as a global pharmaceutical sourcing and distribution services company, navigating a highly competitive landscape that includes direct-to-consumer manufacturers, chain drugstores, and specialty distributors. The company faces significant operational risks stemming from industry consolidation, which may reduce its negotiating power, and the potential insolvency of key customers or suppliers. Notably, as of September 2025, Walgreens and Boots, along with Evernorth Health Services, accounted for 43% of the company’s net accounts receivable. Financial performance is heavily influenced by regulatory and legislative volatility. The company is subject to stringent supply chain security requirements, such as the Drug Supply Chain Security Act (DSCSA) and EU Falsified Medicines Directive, which increase compliance costs. Furthermore, the Inflation Reduction Act (IRA) and various Medicaid reimbursement reforms create uncertainty regarding pricing, manufacturer rebates, and customer demand. COR is also managing a $4.3 billion liability related to a multi-year opioid litigation settlement. Beyond regulatory pressures, the company faces substantial cybersecurity risks, including threats from organized adversaries and AI-driven attacks. While COR maintains a comprehensive information security program, it remains vulnerable to data breaches and third-party supply chain disruptions. Recent financial results have also been impacted by impairment charges, including a full write-down of PharmaLex goodwill.

Filed

Item

Context

May 6, 2026

mda_quarterly

Cencora acquired OneOncology on February 2, 2026, for $7.387 billion to expand its U.S. specialty pharmaceutical leadership and community oncology provider network. Six-month revenue increased 4.7%, driven by strong unit volume growth in the U.S. Healthcare Solutions segment—specifically GLP-1 class diabetes and weight loss products—and growth in European distribution. Gross profit rose 18.6% over six months, aided by LIFO credits from declining manufacturer prices and the RCA and OneOncology acquisitions, though offset by reduced antitrust litigation gains. Operating expenses increased due to integration costs and a $249.5 million impairment of the U.S. Consulting Services business. Interest expenses climbed following the issuance of $3.0 billion in senior notes and $1.5 billion in term loans to fund the OneOncology transaction. Cash flow from operations shifted to a $1.0 billion outflow over six months, primarily due to a $2.2 billion decrease in accounts payable. The company carries a $4.3 billion accrued opioid litigation liability payable over 13 years. Primary risks include foreign exchange volatility—particularly the Turkish Lira and Euro—inflationary pressures on fuel and operating costs, and geopolitical instability in Ukraine and the Middle East.

Feb 4, 2026

mda_quarterly

Cencora reorganized its reporting into U.S. Healthcare Solutions, International Healthcare Solutions, and Other. Quarterly revenue rose 5.5% to $85.9 billion, driven by a $1.0 billion increase in GLP-1 diabetes and weight loss product sales and growth in European distribution. The company expanded its footprint through the $4.6 billion acquisition of OneOncology and the earlier acquisition of RCA. Gross profit increased 20.1% to $3.1 billion, supported by the RCA integration and a $70.2 million LIFO credit resulting from lower brand pharmaceutical prices. However, operating expenses rose 24.8%, including a $249.5 million impairment of the U.S. Consulting Services business. Net interest expense increased 159.2% due to new debt financing for acquisitions. Cash used in operations was $2.3 billion, largely reflecting a $3.5 billion inventory increase to support business volume. Cencora maintains a $4.3 billion accrued liability for opioid litigation, payable over 13 years. Financial analysts should monitor GLP-1 utilization trends, the rate of generic and biosimilar conversion, and foreign exchange volatility, particularly regarding the Turkish Lira.

Nov 25, 2025

business

COR operates as a global pharmaceutical sourcing and distribution services company, navigating a highly competitive landscape that includes direct-to-consumer manufacturers, chain drugstores, and specialty distributors. The company faces significant operational risks stemming from industry consolidation, which may reduce its negotiating power, and the potential insolvency of key customers or suppliers. Notably, as of September 2025, Walgreens and Boots, along with Evernorth Health Services, accounted for 43% of the company’s net accounts receivable. Financial performance is heavily influenced by regulatory and legislative volatility. The company is subject to stringent supply chain security requirements, such as the Drug Supply Chain Security Act (DSCSA) and EU Falsified Medicines Directive, which increase compliance costs. Furthermore, the Inflation Reduction Act (IRA) and various Medicaid reimbursement reforms create uncertainty regarding pricing, manufacturer rebates, and customer demand. COR is also managing a $4.3 billion liability related to a multi-year opioid litigation settlement. Beyond regulatory pressures, the company faces substantial cybersecurity risks, including threats from organized adversaries and AI-driven attacks. While COR maintains a comprehensive information security program, it remains vulnerable to data breaches and third-party supply chain disruptions. Recent financial results have also been impacted by impairment charges, including a full write-down of PharmaLex goodwill.

Forward Estimates

COR filing events and research context

Keep researching COR

Related tickers

Related explainers

Forward Estimates